Denosumab is a synthetic human IgG2 monoclonal antibody. Its therapeutic target is a receptor required for survival and activity of osteoclasts called receptor activator of nuclear factor-κB ligand (RANKL). The presumed mechanism of action of denosumab is that blockage of the receptor reduces osteoclast-mediated bone resorption, thereby maintain bone mineral density. It has been shown to be effective in reducing all major types of osteoporotic fractures in women and in men receiving androgen-deprivation therapy for prostate cancer.
- Prevention of skeletal-related events in adults with bone metastases from solid tumours
s/c twice yearly (osteoporosis).
- ↑ Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006 Feb 23;354(8):821-31
- ↑ Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England journal of medicine. 2009 Aug 20; 361(8):756-65.(Link to article – subscription may be required.)
- ↑ Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. The New England journal of medicine. 2009 Aug 20; 361(8):745-55.(Link to article – subscription may be required.)